Skip to main content
REGENERON PHARMACEUTICALS, INC. logo

REGENERON PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · REGN ISIN · US75886F1075 LEI · 549300RCBFWIRX3HYQ56 US Manufacturing
Open in API
Filings indexed 1,720 across all filing types
Latest filing 2023-06-01 Regulatory Filings
Country US United States of America
Listing US REGN

About REGENERON PHARMACEUTICALS, INC.

https://www.regeneron.com/

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. The company's research and development efforts are focused on a wide range of therapeutic areas, including ophthalmology, cancer, allergic and inflammatory diseases, cardiovascular and metabolic disorders, and rare diseases. Regeneron leverages its expertise in biologics and genetic medicines to translate scientific breakthroughs into transformative treatments for patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings
2023-06-01 English
Proxy Solicitation & Information Statement 2023
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Notice of Exempt Solicitation filed on SEC Form PX14A6G, which is used for shareholder communications that are exempt from proxy solicitation rules. It discusses urging shareholders to vote FOR a shareholder proposal at the company's upcoming annual general meeting. The content focuses on the proposal related to patent practices and drug pricing, but it is not a proxy statement itself, nor is it a report or financial filing. It is a solicitation communication related to a shareholder proposal for the AGM. The document is not a full report, earnings release, or management discussion, but rather a written material submitted pursuant to SEC rules for exempt solicitation. Therefore, it fits best under the category of Proxy Solicitation & Information Statement (PSI). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive solicitation document.
2023-05-18 English
PRIMARY DOCUMENT
Director's Dealing
2023-05-17 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is titled 'SCHEDULE 14A' and is identified as 'Definitive Additional Materials' related to a proxy statement filed under Rule 14a-101. It discusses matters related to the 2023 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, including shareholder voting rights, board leadership succession, and diversity on the board. The content is focused on providing additional information to shareholders to assist in their voting decisions at the annual meeting. This aligns with the definition of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. The document is not the proxy statement itself but additional materials related to it, which still fall under the PSI category. The length and detail confirm it is not a brief announcement or a certification, and it is not a full annual report or other financial filing. Therefore, the appropriate classification is PSI with high confidence.
2023-05-17 English
PRIMARY DOCUMENT
Director's Dealing
2023-05-10 English
10-Q
Interim / Quarterly Report Q1 2023
2023-05-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.